Zacks: Analysts Expect Trillium Therapeutics Inc. (TRIL) Will Post Earnings of -$0.89 Per Share

Wall Street analysts expect Trillium Therapeutics Inc. (NASDAQ:TRIL) (TSE:TR) to post earnings per share (EPS) of ($0.89) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Trillium Therapeutics’ earnings. The lowest EPS estimate is ($1.19) and the highest is ($0.59). Trillium Therapeutics reported earnings per share of ($0.86) during the same quarter last year, which would suggest a negative year over year growth rate of 3.5%. The company is scheduled to announce its next quarterly earnings results on Friday, March 9th.

According to Zacks, analysts expect that Trillium Therapeutics will report full-year earnings of ($3.71) per share for the current fiscal year, with EPS estimates ranging from ($4.76) to ($1.98). For the next fiscal year, analysts anticipate that the firm will report earnings of ($2.70) per share, with EPS estimates ranging from ($3.56) to ($1.62). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Trillium Therapeutics.

Several research firms have recently weighed in on TRIL. Zacks Investment Research raised shares of Trillium Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, September 19th. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Trillium Therapeutics in a research report on Thursday, December 14th. Finally, ValuEngine downgraded shares of Trillium Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, December 15th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Trillium Therapeutics presently has an average rating of “Buy” and an average target price of $13.33.

Several institutional investors and hedge funds have recently added to or reduced their stakes in TRIL. Victory Capital Management Inc. increased its position in shares of Trillium Therapeutics by 88.9% in the 2nd quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 68,970 shares during the last quarter. K2 Principal Fund L.P. bought a new stake in shares of Trillium Therapeutics during the 2nd quarter valued at about $264,000. Virtu KCG Holdings LLC bought a new stake in shares of Trillium Therapeutics during the 2nd quarter valued at about $128,000. Tekla Capital Management LLC bought a new stake in shares of Trillium Therapeutics during the 2nd quarter valued at about $1,980,000. Finally, Sectoral Asset Management Inc grew its position in shares of Trillium Therapeutics by 42.9% during the 2nd quarter. Sectoral Asset Management Inc now owns 183,272 shares of the biotechnology company’s stock valued at $806,000 after buying an additional 55,000 shares during the last quarter. 47.18% of the stock is owned by institutional investors.

Shares of Trillium Therapeutics (NASDAQ:TRIL) opened at $7.45 on Friday. The firm has a market cap of $83.88, a PE ratio of -1.97 and a beta of 1.80. Trillium Therapeutics has a 1 year low of $4.15 and a 1 year high of $13.30. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.33 and a quick ratio of 6.33.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect Trillium Therapeutics Inc. (TRIL) Will Post Earnings of -$0.89 Per Share” was first reported by Week Herald and is owned by of Week Herald. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://weekherald.com/2017/12/29/zacks-analysts-expect-trillium-therapeutics-inc-tril-will-post-earnings-of-0-89-per-share.html.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply